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Abstract
Cancer of unknown primary (CUP) ranges within top 10 cancers in both incidence and mortality. As primary identiﬁcation is crucial to
choosing treatment, guidelines on CUP emphasize the diagnostic strategy. Whether guidelines are complied with, or if they are
indeed helpful, is however unclear. We compared procedures performed in suspected CUP patients with recommendations of
national guidelines to assess external validity of guidelines.
The Danish National Patient Registry (NPR) comprising population data was utilized to identify the suspected CUP patients during
2009 to 2010 and explore exposure to procedures and patient survival. The cohort was investigated in terms of validity of diagnosis
through cross-referencing with the Cancer Registry (CR), which served as gold standard for cancer diagnoses and patients’ cancer
histories.
TheNPRcohort consistedof 542patients (275males, 264 females) ofwhom210 (38.7%) had aCUPdiagnosis conﬁrmed.Within the
cohort, 347 patients (64.0%) had a registration in CRmatching with the NPR registration. Exposure to diagnostic procedures included
biopsy (n=439, 81.0%) and image modalities (n=532, 98.2%). Survival was poor with 67 (12.4%) individuals alive after 4 years.
The validity of a CUP diagnosis in NPRwas low when using data from CR as reference. More than half the suspected CUP patients
had a previous cancer diagnosis with CUP being themost frequent. Patients were diagnosed in compliance with guidelines indicating
high external validity, but less than 1 quarter had their primary identiﬁed and the 1-year survival was approximately 20%. Research is
needed to develop efﬁcacious methods for primary detection.
Abbreviations: CR = Cancer Registry, CRS = Civil Registration System, CUP = cancer of unknown primary, NPR = National
Patient Registry.
Keywords: clinical guideline, CUP, external validity, occult cancer, unknown primary
1. Introduction
Cancer of unknown primary (CUP) accounts for 3% to 5% of all
cancer malignancies,[1–3] placing it among the top 10 cancers in
terms of incidence andmortality amongmen andwomen.[4,5] The
prognosis is poor and severe morbidity often coexists at
diagnosis, and, thus, being diagnosed with CUP is highly taxing
on patients.[6–9] Since identiﬁcation of the primary is crucial to
treatment triage and prognosis,[10] an effective diagnostic
strategy must be initiated when CUP is suspected. Not even
postmortem investigation will necessarily lead to identiﬁcation of
the primary.[11] In lieu of evidence from meta-analyses or
systematic literature reviews, the best available evidence is
constituted by clinical guidelines. To what degree diagnostic
investigations comply with guidelines, or if such compliance is
indeed helpful to patients, is not clear. One recommended
approach for assessment of external validity is to compare results
of randomized controlled trials (measuring efﬁcacy) with results
of cohort studies of the same intervention (measuring effective-
ness) using routine data.[12,13] In this study, registered procedures
carried out in the routine in this type of patients were compared
with recommendations of clinical guidelines to assess the external
validity of the guidelines.
Denmark has the dubious honour of holding the world record
on cancer incidence with 338 new cases per 100,000 in 2012,
compared with 273 in the UK, 284 in Germany, 296 in Canada,
and 318 in the United States.[14] In 2007, this position in
combination with a cancer death rate higher than in surrounding
countries, prompted the National Danish Health Authority to
establish patient pathways for diagnostics and treatment. By
January 2009, these integrated cancer pathways were ofﬁcially
implemented in the Danish healthcare system. The national
pathway for CUP constituted the reference guideline used as
theoretical foundation for this article.[15] The terms guideline and
pathway are used interchangeably in the remainder of the article.
Using 3 national databases, the aim of the present study was to
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1
determine the validity of registered CUP diagnoses, describe
patients’ cancer history prior to the CUP diagnosis, assess if the
clinical guideline for CUP had been complied with, and analyze
survival following a CUP diagnosis with and without censoring
for subsequent speciﬁc cancers.
2. Materials and methods
2.1. Data registries
Due to the comprehensive registration of each contact between a
patient and the health care sector in Denmark, it is possible to
study relatively large cohorts of patients and their history pre and
post entry into a trial cohort. Further, thanks to personal ID
numbers and free access to healthcare, 98% of which is public,
Danish registries are not hampered by selection bias determined
by access. We obtained pseudo-anonymised data from 3
registries: the National Patient Register (NPR), the Cancer
Register (CR), and the national Civil Registration System (CRS);
for details, see Supplemental Digital Content 1, http://links.lww.
com/MD/B665.
In NPR, a primary diagnosis must be registered at any
admission. When a patient is discharged, the admission is
ascribed to the most likely diagnosis at the time of discharge.
Registrations in CR, on the other hand, are recorded alongside
information on what clinical investigations conﬁrm the presence
of cancer.[16] Consequently, registrations in CR reﬂect the
knowledge at a later time point, when the result of amore decisive
diagnostic workup is available, and divergences between
registries are to be expected. In 2012, CR underwent thorough
validation within the ﬁelds of lung and breast cancer (based
on data from 2006). This validation included assessments
of accuracy and completeness of the register with cases of
disagreement explored through identiﬁcation of the original data
(i.e., patient ﬁles, pathology reports, etc.). The conclusion was
that the register was valid with low risk of wrong or missing
data.[16] Assuming that the register is equally well managed
within the ﬁeld of CUP, CR was considered the more valid source
of information compared to NPR, and cancer diagnoses in CR
were considered true, whereas diagnoses in NPR were perceived
as tentative. This assumption is related to the data validity rather
than to the validity of the diagnosis.
The combination of NPR and CR registrations with the CRS
data enabled both a validation of NPR registrations and analyses
of CUP-patients’ diagnostic processes and cancer histories.
The CR data were not restricted to the 2009 to 2010
observation period. The follow-up for the cohort ended at the
date of data request, namely August 1, 2013.
Permission to store the data was obtained by the Danish Data
Protection Agency. No further permissions were required as
registry studies do not require permission from the Regional
Committee of Health Research Ethics for Southern Denmark.
2.2. CUP guideline
The authors of the national guideline state that it is based on
evidence, previous clinical guidelines, or expert consensus.[15]
Speciﬁcally, 3 references are mentioned as the basis for the CUP
guideline: a clinical guideline published by the Co-operative
Cancer Departments,[17] a clinical guideline published by the
Danish Association for Head and Neck Oncology,[18] and the
clinical guideline published by Briasoulis et al[19] in 2005. In
short, the recommendations given in the national guideline were
that patients suspected of CUP should be investigated through
medical history, clinical investigation, blood sampling, image
modalities, and biopsy.
Although the speciﬁc use of the scientiﬁc publications
supporting these recommendations was not clear, the outline
of steps within the diagnostic process facilitated explorations of
whether or not the recommendations were complied with.
2.3. Statistical evaluation
Descriptive statistics comprised frequencies and respective
percentages. x2 tests were applied to test for differences between
groups. Kaplan–Meier plots were used to graphically present
patient survival over time after index-CUPs, censoring for
another cancer diagnosis than CUP. Twenty-ﬁfth, 50th, and 75th
percentiles of survival time were supplemented by respective 95%
conﬁdence intervals (95% CI). All statistical analyses were
conducted with Stata/IC 13.1 (StataCorp, College Station, TX).
3. Results
Within the 2009 to 2010 time frame, 543 patients were identiﬁed
with at least 1 CUP diagnosis (index-CUP) in Danish hospitals.
One patient was excluded as his/her date of death was registered
prior to the index-CUP admission date. Thus, 542 patients, all of
whom had their data registered in the CR, made up the project
cohort. Observations from 27 patients were adjusted as their
date of death (obtained from CRS) preceded that of diagnosis
(obtained from NPR). Date of death was considered the more
reliable of the 2.
3.1. Population and cancer registrations
The 542 patients within the CUP cohort were distributed equally
across age ranges and gender with no statistically signiﬁcant
differences (Table 1, see Fig. 1 for ﬂowchart). The ﬁrst age group
included subjects from 0 to 59 so as not to exclude patients. Three
patients were younger than 18 years old, that is, 1, 9, and 13 years
of age.
A total of 347 patients (64.0%) from the cohort had a hit in
CR. A hit was deﬁned as a CR diagnosis within the time interval
between 30 days prior to admission until 30 days after discharge
as registered in NPR. All patients were, however, registered in CR
at some point during their lives. Almost half of the patients had
no preindex diagnosis in that they had no cancer registered prior
to their index-CUP (n=264, 48.7%). Approximately one third
had a history with a speciﬁc cancer (n=185, 34.1%), and the
remaining patients (n=93, 17.2%) had either a previous CUP
diagnosis or both a CUP and a speciﬁc cancer (Table 1).
Subsequent to the index-CUP, 16 patients had a cancer registered
in CR. Among these patients, 10 (2.9%)were registered with a hit
and 6 (3.1%) were not registered with a hit (please see Table 2)
and thus had postindex diagnoses.
A total of 439 patients (81.0%) had a biopsy taken, and 532
(98.2%) underwent diagnostic imaging (e.g., computed tomog-
raphy [CT] and X-ray). Additional imaging within the speciality
of nuclear medicine was performed for 327 patients (60.3%).
Some patients had procedures registered withinmedical oncology
(n=213, 39.3%), and 78 (35.6%) received radiation therapy
(Table 1).
Between the index-CUP diagnosis and the date of the last
observation (July 7, 2013), 475 (87.5%) of the patients had died.
Of these, 261 (48.2%) died within 30 days after discharge from
the hospital, 115 patients (21.2%) died within 90 days, and 86
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(15.9%) within 180 days after discharge. Of the subgroup of
patients not diagnosed with a speciﬁc cancer subsequent to their
index-CUP, 67 (38.1%) died within 30 days, 25 (14.2%) within
90 days, and 21 (11.9%) within 180 days (Table 1). Seven of the
19 patients diagnosed with a speciﬁc cancer subsequent to their
CUP diagnosis died: 4 within 90 days, 3 between 90 and 180 days
(data not shown elsewhere).
3.2. Validity of cancer diagnoses at index
When dates of diagnosis from CR and NPR were compared, 195
(36.0%) of patients registered in NPR were not registered with a
cancer in CR within a time frame of ± 30 days. Furthermore, 127
patients (23.4%) were registered as having speciﬁc cancers, and
only 210 (38.7%) were registered in CR as having CUP at the
time corresponding to their index-diagnosis in NPR (data not
shown elsewhere). The discrepancies between registers indicate
that about half of patients who were initially given a CUP
diagnosis at hospital admission were later diagnosed with a
speciﬁc cancer or were not diagnosed with cancer on the basis of
diagnostic tests. Diagnoses from CR in conjunction with index-
CUP from NPR are presented in Table 2, alongside previous and
later diagnoses.
3.3. Cancer history
As the CR included data on patients from birth, data were
explored for patterns in diagnoses to investigate differences
between patients with a hit and patients without a hit. A total
of 347 patients (64.0%) had a hit in CR. Among these patients,
74 (21.3%) had 1 previous cancer with 4 being CUPs, and
Patients diagnosed 
with CUP in LPR:
N=542
Hit in CR
N=347
NPR: 
184,835 indviduals admitted 
with any CUP-relevant 
diagnosis between 2008-
2010
CUP not primary 
diagnosis or 
Index-diagnosis 
outside 2009-2010
No hit in CR
N=195
Figure 1. Flowchart of patients. A total of 184,835 patients had any kind of
CUP registration in the National Patient Registry (NPR). Restricting the
population to relevant registrations decreased the population size to 542 of
whom 347 had a hit in Cancer Registry (CR). CUP = cancer of unknown
primary.
Table 1
Study population according to gender, age group, diagnoses, mortality, and diagnostic procedures.
Males Females
Ages Ages
Total, n (%) P-value0–59 60–69 70-79 80+ 0–59 60–69 70–79 80+
70 [25.2] 85 [30.6] 69 [24.8] 54 [19.4] 64 [24.2] 71 [26.9] 80 [30.3] 49 [18.6] 542 (100) 0.53
Preindex diagnosis
No cancer 41 [28.9] 39 [27.5] 33 [23.2] 29 [20.4] 31 [25.4] 28 [23.0] 42 [34.4] 21 [17.2] 264 (48.7) 0.25
Speciﬁc cancer 15 [16.5] 31 [34.1] 23 [25.3] 22 [24.2] 19 [20.2] 25 [26.6] 27 [28.7] 23 [24.5] 185 (34.1) 0.70
CUP 13 [35.1] 13 [35.1] 9 [24.3] 2 [5.4] 12 [32.4] 13 [35.1] 9 [24.3] 3 [8.1] 74 (13.7) 0.97
Speciﬁc cancer and CUP 1 [12.5] 2 [25.0] 4 [50.0] 1 [12.5] 2 [18.2] 5 [45.5] 2 [18.2] 2 [18.2] 19 (3.5) 0.53
Postindex diagnosis
No cancer 13 [14.9] 24 [27.6] 26 [29.9] 24 [27.6] 14 [15.7] 21 [23.6] 27 [30.3] 27 [30.3] 176 (32.5) 0.94
Speciﬁc cancer 7 [43.8] 4 [25.0] 5 [31.3] 0 [0] 1 [33.3] 1 [33.3] 0 [0] 1 [33.3] 19 (3.5) 0.09
CUP 0 [0] 0 [0] 0 [0] 0 [0] 0 [0] 0 [0] 0 [0] 0 [0] 0 (0) —
Speciﬁc cancer and CUP 0 [0] 0 [0] 0 [0] 0 [0] 0 [0] 0 [0] 0 [0] 0 [0] 0 (0) —
Diagnostic procedures and treatment
Biopsy 59 [25.8] 77 [33.6] 57 [24.9] 36 [15.7] 55 [26.2] 62 [29.5] 63 [30.0] 30 [14.3] 439 (81.0) 0.62
Nuclear medicine investigation 54 [30.5] 63 [35.6] 39 [22.0] 21 [11.9] 45 [30.0] 46 [30.7] 40 [26.7] 19 [12.7] 327 (60.3) 0.71
Radiology 70 [25.5] 85 [30.9] 67 [24.4] 53 [19.3] 63 [24.5] 69 [26.8] 79 [30.7] 46 [17.9] 532 (98.2) 0.41
Medical oncology 36 [34.3] 45 [42.9] 20 [19.0] 4 [3.8] 40 [37.0] 30 {27.8] 31 [28.7] 7 [6.5] 213 (39.3) 0.10
Radiation therapy 27 [23.5] 32 [27.8] 29 [25.2] 27 [23.5] 21 [26.9] 18 [23.1] 29 [31.2] 10 [12.8] 78 (35.6) 0.13
Mortality
Mortality (total) 57 [22.7] 77 [30.7] 64 [25.5] 53 [21.1] 50 [22.3] 61 [27.2] 70 [31.1] 43 [19.2] 475 (87.6) 0.55
Mortality at 30 d 24 [18.2] 30 [22.7] 37 [28.0] 41 [31.1] 19 [14.7] 29 [22.5] 49 [38.0] 31 [24.8] 261 (48.2) 0.34
Mortality at 90 d 12 [17.6] 22 [32.4] 20 [29.4] 14 [20.6] 7 [14.9] 11 [23.4] 18 [38.3] 11 [23.4] 115 (21.2) 0.64
Mortality at 180 d 9 [23.7] 13 [34.2] 11 [28.9] 5 [13.2] 11 [22.9] 16 [33.3] 9 [18.8] 12 [25.0] 86 (15.9) 0.48
Mortality (no cancer diagnosis postindex) 10 [12.5] 22 [27.5] 23 [28.8] 25 [31.3] 10 [13.9] 20 [27.8] 22 [30.6] 20 [27.8] 176 [100] 0.97
Mortality at 30 d, no cancer 3 [9.7] 7 [22.6] 7 [22.6] 14 [45.2] 4 [11.1] 8 [22.2] 13 [36.1] 11 [30.6] 67 (38.1) 0.57
Mortality at 90 d, no cancer 1 [6.7] 4 [26.7] 8 [53.3] 2 [13.3] 1 [10.0] 2 [20.0] 3 [30.0] 4 [40.0] 25 (14.2) 0.44
Mortality at 180 d, no cancer 1 [12.5] 3 [37.5] 3 [37.5] 1 [12.5] 1 [7.7] 5 [38.5] 2 [15.4] 5 [38.5] 21 (11.9) 0.51
Note: [% by age and pre- or postindex], (% of total population), the postindex diagnoses do not add up to 100%, which is most likely due to mortality within the cohort, the P value is calculated for gender
differences across age groups.
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18 (5.2%) had more than 1 previous cancer 1 of which was a
CUP. In comparison, among the patients who did not have a hit in
CR 142 (72.8%) had 1 previous cancer with 67 CUPs, and 45
(23.1%) had more than 1 previous cancer including 13 CUPs.
These differences are substantial, and may indicate either that a
history of cancer is not a predictor for later CUP diagnosis in CR,
or patients who have a previous cancer but no hit constitute a
group of patients who are not exposed to follow-up investigations
due to poor performance status, comorbidity, or other problems
that prevent further diagnostics. In terms of diagnoses subsequent
to the index-CUP inNPR, only 18patientswere registered.Among
these, the patients with a hit accounted for 10 patients (2.9%)with
a later diagnosis and 8 patients (4.1%) without a hit. None of the
later diagnoses were CUPs (see Table 2).
3.4. Clinical guideline compliance
It is not clear from the current dataset to what degree patients had
their medical history assessed, or if they were exposed to clinical
investigation or blood sampling. In terms of image modalities,
however, 532 patients were subjected to at least 1 (ﬁrst-line)
image modality (98.2%). Also, 372 patients (60.3%) had a
nuclear medicine procedure (second-line image modality)
(Table 1). As many as 439 (81.0%) patients had a biopsy taken.
With regard to treatment, 213 patients had registrations within
the oncological specialty (39.9%), and 78 had at least 1
registration of radiation therapy (35.6%) (Table 1).
3.5. Survival
The prognosis of the patients was poor. The survival curve
declined rapidly and steeply (Fig. 2). Median survival from the
index-CUP was less than 5 months (129 days, 95% CI: 99–163).
One quarter of patients died within 34 days (95%CI: 25–44) and
75%of patients were dead after 503 days (95%CI: 406–717). At
the ﬁnal registration after 4 years, the chance of survival had
descended so at the end of study 475 (87.6%) patients had died
(Table 1, Fig. 2).
4. Discussion
According to the NPR, during 2009 and 2010 a total of 542
patients were diagnosed with CUP at discharge from hospitals in
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Denmark. The validity of an NPR CUP diagnosis was low, as
only 40.6% of the NPR population had their initial diagnosis
conﬁrmed. Patients’ histories showed that the most frequent
previous cancer was CUP. This ﬁnding calls for further
exploration in future studies to ﬁnd a plausible explanation
for an apparent lack of consequence of this diagnosis when it was
ﬁrst used, including an analysis of whether the health care system
has temporarily lost the patient of sight or found no grounds for
further examination and treatment. The low validity of NPR
diagnosis and the time span between ﬁrst (CR) CUP and the
index-CUP may not only reﬂect the work-up challenge for the
diagnosis of CUP, but in particular also the difﬁcult situation of
the patients and their kin.
The equal distribution of the CUP diagnoses across age and
gender was unexpected in view of the typical increase of most
cancers with age. Since we could not penetrate deeper into the
data, one should be careful to interpret this. However, a
speculative possibility could be that cancers in young people are
rather uncommon and lack age-related characteristics and
therefore perhaps easier downplayed or overlooked. In addition,
they are often aggressive and diagnosed at a more advanced stage
making detection of the primary more difﬁcult.[20] Albeit rare,
some cancer forms are inherited and often present at an early age.
Colonic cancers (adenocarcinomas) are less common in young
adults but more often linked to a genetic condition that puts the
person at higher risk. Thus, they constitute 1 example of
malignancies with a high mortality rate among youngsters,[21]
particularly so because screening for them is not recommended in
young adulthood.[22]
Compliance with the work-up part of guidelines was fairly high
in that 98.2% of patients underwent diagnostic imaging and
81.0%had a biopsy taken, suggesting that the external validity of
results was high, provided that cohort members had been offered
the best possible opportunities of identifying their primary.
However, only 23.4% of patients had their primary identiﬁed at
index (according to CR), so despite having undergone recom-
mended diagnostic procedures, only one-fourth of patients had a
speciﬁc cancer diagnosed. The guideline[15] does not indicate how
many primaries should be identiﬁed. Thus, it remains unclear to
what degree this low number reﬂects insufﬁcient evidence
supporting the guideline.
Survival expectation was low with only 12.4% alive at the end
of the study period of 4 years. In CUP, survival may be correlated
with insufﬁcient diagnostics in several ways: ﬁrst, the more
speciﬁc the diagnosis, the more speciﬁc treatment regimens can be
instituted, whereas true CUP is treated with more generic
chemotherapies of less speciﬁcity and, thus, presumably less
efﬁcacy in the vast majority of these cancers. Furthermore, the
delay in diagnostic pathways due to futile investigations may lead
to deterioration of patient performance to such a low status that it
contraindicates treatment when the workup is ﬁnished. The
median survival of 129 days seems to suggest that recommended
procedures for diagnosing CUP are insufﬁcient. The conﬁdence
intervals of the survival estimates may seem wide; however,
perhaps not surprisingly wide considering that the CUP diagnosis
covers multiple cancer forms of varying aggressiveness and
management, the latter probably ranging from no treatment to
aggressive radio-chemotherapy.
4.1. Comparison with other research ﬁndings
Epidemiological research in CUP is limited.[4,23] The general
consensus in the literature is that CUP is an aggressive cancer with
an unfavorable prognosis accounting for a considerable part of
malignant cancers.[4,24] The poor survival in our material agrees
with data from Sweden, where CUP survival after 1 year was
estimated to 20%.[25] Together, these ﬁndings call for further
research into this cancer in particular.[1–5] Furthermore, research
into the modalities used for diagnosis of CUP may potentially
change the prognosis of these patients. First, immunohistochemi-
cal tumor markers have been mentioned as potentially
effective,[26,27] and second, front-line PET/CT has been shown
to identify 45% (range 25%–57%) of primary tumors in CUP
patients.[28–31] The most recent European Society for Medical
Oncology guideline presents a subdivision of CUP cancers on the
basis of pathology and recommends physical examination, blood
and biochemical analyses, CT, while only recommending PET/
CT for a subgroup of patients. The evidence supporting these
recommendations is based on retrospective cohorts or case-
control studies, or prospective cohort studies.[27] The recom-
mendations are clearly related to references, which is a clear
improvement to the Danish guideline. It is not, however, stated
how many primaries one can expect to ﬁnd on the basis of the
diagnostic work-updescribed in the guideline. A typical example
of delayed PET/CT is shown in Fig. 3.
4.2. Strengths and limitations
Our cohort was determined on the basis of NPR. Because of the
low validity of this register, our analyses were conducted on
patients who did and did not have their CUP conﬁrmed. It is not
possible at this point to know how results would have changed if
only the group with a valid CUP had been included. Meanwhile,
the Danish registries are excellent for research purposes in that
they include data on all patients, and that all patients include the
entire population as a reference group. Furthermore, the
possibility to cross-reference data enables studies that may serve
as a basis for future studies and discussions about registration
Figure 3. PET/CT in CUP patients. Left: man aged 57 with a biopsy-veriﬁed
adenocarcinoma metastasis in the liver from a hitherto undetected origin. PET/
CT revealed a primary in the sigmoideum (arrow). Right: woman aged 50 with a
tumor on her back, diagnosed 4months later as ametastasis from an unknown
primary. PET/CT performed 2 months later revealed multiple metastases
precluding identiﬁcation of the primary. Courtesy: Henrik Petersen, Department
of Nuclear Medicine, Odense University Hospital, Denmark.
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practice. In our study, a CUP diagnosis was considered valid
when the diagnostic workup had been performed fully to rule out
organ-speciﬁc cancers. We were not able to test if our assumption
that the CR registrations were actually based on pathologic
ﬁndings with regard to the CUP diagnosis, which presumably
may be more difﬁcult to make than the diagnoses of lung and
breast cancer. In future studies, data from the pathology register
would serve to further inform the ﬁndings.
The date of discharge was used as a reference date for the CUP
diagnosis to make sure that all relevant codes of procedures
attached to each admission were included in the analyses. Some
results may have changed slightly had the date of admission been
used instead. For instance, patients are, by deﬁnition, alive during
their entire admission to hospital, so the survival would have
increased somewhat. How much depends on the duration of the
admissions, which was not explored here. In line with this, as
the duration of admission can vary substantially, it would be
interesting in future studies to subdivide diagnostic procedures
into 3 time windows, that is, prior to, during, and after
admission/discharge.
Only 1 author categorized the codes from NPR into relevance
and clinical speciality.
4.3. Implications for clinical practice
As this article was based on a cohort and epidemiological
methods, the results are of limited immediate value for clinical
practice. To inform clinical practice, it would be important for
future publications to include an assessment of what diagnostic
procedures are most effective in conﬁrming the CUP diagnosis,
how early detection may be achieved, and to what degree this
may inﬂuence the choice and starting point of therapy. Two
examples of initiatives facilitating early detection could be the set-
up multidisciplinary diagnostic centers[32] or the rapidly evolving
ﬁeld of immunohistochemical markers.[26]
4.4. Perspectives for future research
Since the data for this project were registered, the diagnostic
pathways for CUP (and other cancers) have been updated. Now,
an administrative code is applied to all pathways at initiation and
termination of the pathway making it possible to identify which
procedures have been registered in the diagnostic workup of a
speciﬁc cancer pathway without making assumptions concerning
timing of procedures. Furthermore, 1 aspect that would have
informed the current study was which diagnostic cancer
pathways the patients had been assigned to. This information
was not available to us, but is with the updated codes. In this
sense, the current study could be used as amodel for updated data
collection with the possibility for further explorations as the
registration practice has been expanded.
4.5. Performance status of patients
Patients’ performance status is of utmost importance in the
clinical decision making. As mentioned by Shaw, Adams, Jordan,
Crosby,[10] and the Danish Health Authority,[15] a considerable
subsection of the CUP population may not have been referred to
further diagnostic workup or treatment due to poor general
health status. How frequently this is the case can be estimated
with the recently introduced administrative codes for cancer
diagnostic pathways. In addition, it is uncertain if and after how
long time a patient with negative ﬁndings in 1 organ-speciﬁc
pathway is referred to another, in particular because there is
no single medical specialty taking care of all suspected CUP
patients.
5. Conclusion
We found that the validity of CUP diagnoses in NPR is low and
that cancer history, and a history of a CUP diagnosis in
particular, is relevant as a risk factor for a later CUP diagnosis.
Clinicians in Danish hospitals follow the CUP guidelines fairly
well in providing recommended diagnostic procedures to most
patients, but apparently without improving the survival.
These ﬁndings warrant further research focusing on early and
more efﬁcient detection of the primary and rapid, targeted
treatment, preferably also focusing on the inﬂuence of patient
performance on the implementation of the recommended
diagnostic workup. Danish registries have the potential to serve
as tools for these efforts. However, one should not rely on a single
register (particularly if that register is NPR). Furthermore,
one should ascertain that pathology data are available in all
patients.
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